



## **Commencement of Multi-Centre Clinical Trial for CathRx’s ElectroPulse™ PFA System in Atrial Fibrillation (AF) Patients**

- First patients enrolled in ElectroPulse AF Multi-Centre Clinical Trial
- Five procedures completed to date across two sites in Adelaide and Newcastle.
- Key step towards CE Mark approval and commercialisation of ElectroPulse PFA System

### **Sydney, Australia - 19 November 2025;**

CathRx Ltd (“CathRx” or “the Company”) is pleased to announce the commencement of its Multi-Centre Clinical Trial (ElectroPulse AF) evaluating the ElectroPulse™ Pulsed Field Ablation (PFA) System for atrial fibrillation (AF). The first sites in Adelaide and Newcastle mark a major milestone towards CE Mark approval and commercialisation.

This milestone follows the compelling mid-term results from CathRx’s First-in-Human (FIH) study, presented in a Late-Breaking Clinical Trial session at the Asia Pacific Heart Rhythm Society (APHRS) Scientific Meeting in Japan on 14 November 2025. The ElectroPulse PFA System is purpose-engineered for electrophysiologists as a new standard for precision and safety in AF ablation therapy.

“The commencement of this multi-centre trial is an important step towards CE Mark approval and commercialisation of the ElectroPulse PFA System, bringing us closer to redefining AF treatment for patients and clinicians worldwide,” said Ian Fong, Managing Director of CathRx.

Following this successful start, CathRx will continue to enrol additional clinical trial sites in the coming weeks as part of the ElectroPulse AF Multi-Centre Clinical Trial. The study is expected to enrol up to 200 patients across multiple sites in Australia and Europe.

The ElectroPulse AF Multi-Centre Clinical Trial received MRFF funding from the Australian Government’s Targeted Translation Research Accelerator program for diabetes and cardiovascular disease, delivered by MTPConnect.

**ENDS**

Authorised for release by Ian Fong, Managing Director

### **Media Contact:**

Ian Fong

Managing Director

Email: [ian.fong@cathrx.com](mailto:ian.fong@cathrx.com);

Phone: +61 411 421 354

Website: [www.cathrx.com](http://www.cathrx.com);

### **About CathRx Ltd**

CathRx Ltd is an Australian medical device company developing next-generation cardiac electrophysiology and ablation technologies. Its patented modular catheter platform has been designed in collaboration with world-leading cardiologists and developed in Australia. CathRx’s mission is to make advanced, safer, and more efficient cardiac ablation accessible globally - improving outcomes for patients and families living with cardiac rhythm disorders.